Aberrant frequency of TNFR2-expressing CD4+ FoxP3+ regulatory T cells in nasopharyngeal carcinoma patients.

[1]  Dong-Hua Yang,et al.  BCL-2 expression promotes immunosuppression in chronic lymphocytic leukemia by enhancing regulatory T cell differentiation and cytotoxic T cell exhaustion , 2022, Molecular Cancer.

[2]  Xin Chen,et al.  Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis , 2020, Annals of translational medicine.

[3]  C. Yean,et al.  Technical Considerations in Ex Vivo Human Regulatory T Cell Migration and Suppression Assays , 2020, Cells.

[4]  T. Tsuzuki,et al.  Increased infiltration of CCR4‐positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis , 2019, The Prostate.

[5]  Li Li,et al.  Increased frequency of regulatory T cells in the peripheral blood of patients with endometrioid adenocarcinoma. , 2019, Oncology letters.

[6]  C. M. Eischen,et al.  Targeting the Bcl-2 Family in B Cell Lymphoma , 2019, Front. Oncol..

[7]  Alexander J. Nelson,et al.  Activated human Foxp3+ regulatory T cells produce membrane‐bound TNF , 2018, Cytokine.

[8]  D. Ma,et al.  Increased Regulatory T Cells in Peripheral Blood of Acute Myeloid Leukemia Patients Rely on Tumor Necrosis Factor (TNF)-α–TNF Receptor-2 Pathway , 2018, Front. Immunol..

[9]  Man Chen,et al.  The detection and significance of T cells in nasopharyngeal carcinoma patients , 2018, Journal of cancer research and therapeutics.

[10]  Z. Qin,et al.  TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors , 2018, Front. Immunol..

[11]  R. Bell,et al.  Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion , 2018, Leukemia.

[12]  J. Tosello,et al.  Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology , 2018, Front. Immunol..

[13]  D. Klinman,et al.  Blockade of TNFR2 signaling enhances the immunotherapeutic effect of CpG ODN in a mouse model of colon cancer , 2018, Science Signaling.

[14]  D. Ma,et al.  Aberrant frequency of TNFR2+ Treg and related cytokines in patients with CIN and cervical cancer , 2017, Oncotarget.

[15]  D. Faustman,et al.  TNFR2: A Novel Target for Cancer Immunotherapy. , 2017, Trends in molecular medicine.

[16]  Zhonghua Zhao,et al.  Clinical implications of tumor necrosis factor receptor 2 in breast cancer. , 2017, Oncology letters.

[17]  R. Foster,et al.  Targeting TNFR2 with antagonistic antibodies inhibits proliferation of ovarian cancer cells and tumor-associated Tregs , 2017, Science Signaling.

[18]  Xin Chen,et al.  Targeting TNFR2, an immune checkpoint stimulator and oncoprotein, is a promising treatment for cancer , 2017, Science Signaling.

[19]  S. Sakaguchi,et al.  Regulatory T cells in cancer immunotherapy , 2016, Cell Research.

[20]  E. Elkord,et al.  Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting , 2016, Vaccines.

[21]  T. Merghoub,et al.  IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients , 2016, Tumor Biology.

[22]  Z. Zhan,et al.  Expression of TNFR2 by regulatory T cells in peripheral blood is correlated with clinical pathology of lung cancer patients , 2015, Cancer Immunology, Immunotherapy.

[23]  S. H. van der Burg,et al.  Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry , 2015, Cancer Immunology, Immunotherapy.

[24]  A. Tsun,et al.  FOXP3+ regulatory T cells and their functional regulation , 2015, Cellular and Molecular Immunology.

[25]  A. Wei,et al.  Lenalidomide‐based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients , 2014, American journal of hematology.

[26]  X. Bian,et al.  The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment , 2014, BioMed research international.

[27]  Wei Sun,et al.  Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. , 2014, International journal of oncology.

[28]  A. Wei,et al.  Reducing TNF Receptor 2+ Regulatory T Cells via the Combined Action of Azacitidine and the HDAC Inhibitor, Panobinostat for Clinical Benefit in Acute Myeloid Leukemia Patients , 2013, Clinical Cancer Research.

[29]  J. Karbach,et al.  Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans , 2013, Proceedings of the National Academy of Sciences.

[30]  M. Quinn,et al.  Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment. , 2013, Clinical immunology.

[31]  M. Plebanski,et al.  TNFR2 Expression on CD25hiFOXP3+ T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing Effectors , 2013, Front. Immunol..

[32]  M. Tsai,et al.  Association of interleukin-10 (IL10) promoter genotypes with nasopharyngeal carcinoma risk in Taiwan. , 2013, Anticancer research.

[33]  S. Tsao,et al.  Enhanced IL-6/IL-6R Signaling Promotes Growth and Malignant Properties in EBV-Infected Premalignant and Cancerous Nasopharyngeal Epithelial Cells , 2013, PloS one.

[34]  M. Netea,et al.  TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment , 2013, The Journal of Immunology.

[35]  P. Liu,et al.  Prognostic Role of Serum Cytokines in Patients with Nasopharyngeal Carcinoma , 2012, Oncology Research and Treatment.

[36]  Xiangpei Li,et al.  CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood , 2012, Inflammation.

[37]  Lifeng Liu,et al.  CCL21/CCR7 Prevents Apoptosis via the ERK Pathway in Human Non-Small Cell Lung Cancer Cells , 2012, PloS one.

[38]  Xin Song,et al.  Correlation between CD4+CD25+Treg cells and CCR4 in nasopharyngeal carcinoma , 2011 .

[39]  Jiaqiang Huang,et al.  TNF optimally activatives regulatory T cells by inducing TNF receptor superfamily members TNFR2, 4‐1BB and OX40 , 2011, European journal of immunology.

[40]  C. Qian,et al.  Serum CCL2 and serum TNF-α--two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. , 2011, European journal of cancer.

[41]  T. Scriba,et al.  Novel application of Ki67 to quantify antigen-specific in vitro lymphoproliferation , 2010, Journal of immunological methods.

[42]  Q. Ye,et al.  Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis B-related hepatocellular carcinoma after curative resection , 2010, Gut.

[43]  A. Hurwitz,et al.  Expression of Costimulatory TNFR2 Induces Resistance of CD4+FoxP3− Conventional T Cells to Suppression by CD4+FoxP3+ Regulatory T Cells , 2010, The Journal of Immunology.

[44]  R. Wiltrout,et al.  Co‐expression of TNFR2 and CD25 identifies more of the functional CD4+FOXP3+ regulatory T cells in human peripheral blood , 2010, European journal of immunology.

[45]  C. Zhong,et al.  Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[46]  T. Whiteside,et al.  Generation and Accumulation of Immunosuppressive Adenosine by Human CD4+CD25highFOXP3+ Regulatory T Cells* , 2009, The Journal of Biological Chemistry.

[47]  A. Darabi,et al.  Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy , 2009, Cancer Immunology, Immunotherapy.

[48]  F. Liu,et al.  Overexpression of TNF‐α and TNFRII in invasive micropapillary carcinoma of the breast: clinicopathological correlations , 2008, Histopathology.

[49]  D. Männel,et al.  Cutting Edge: Expression of TNFR2 Defines a Maximally Suppressive Subset of Mouse CD4+CD25+FoxP3+ T Regulatory Cells: Applicability to Tumor-Infiltrating T Regulatory Cells1 , 2008, The Journal of Immunology.

[50]  D. Olive,et al.  CD8+CD28− T Regulatory Lymphocytes Inhibiting T Cell Proliferative and Cytotoxic Functions Infiltrate Human Cancers1 , 2007, The Journal of Immunology.

[51]  Zheng Zhang,et al.  Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. , 2007, Gastroenterology.

[52]  J. Woo,et al.  Increase in circulating Foxp3+CD4+CD25high regulatory T cells in nasopharyngeal carcinoma patients , 2007, British Journal of Cancer.

[53]  M. Joshi,et al.  Tumor infiltrating Foxp3+ regulatory T‐cells are associated with recurrence in pathologic stage I NSCLC patients , 2006, Cancer.

[54]  A. Banham,et al.  Function and recruitment of mucosal regulatory T cells in human chronic Helicobacter pylori infection and gastric adenocarcinoma. , 2006, Clinical immunology.

[55]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[56]  S. Hwang,et al.  Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.

[57]  Edward Y. Kim,et al.  TNF Receptor Type 2 (p75) Functions as a Costimulator for Antigen-Driven T Cell Responses In Vivo1 , 2006, The Journal of Immunology.

[58]  V. Diehl,et al.  Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. , 2005, Cancer research.

[59]  T. Murakami,et al.  Chemokine receptors and melanoma metastasis. , 2004, Journal of dermatological science.

[60]  Edward Y. Kim,et al.  Critical Role of TNF Receptor Type-2 (p75) as a Costimulator for IL-2 Induction and T Cell Survival: A Functional Link to CD281 , 2004, The Journal of Immunology.

[61]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[62]  M. Tsai,et al.  The elevated serum interleukin-6 correlates with the increased serum butyrate level in patients with nasopharyngeal carcinoma. , 2003, Oncology reports.

[63]  F. Ramsdell,et al.  An essential role for Scurfin in CD4+CD25+ T regulatory cells , 2003, Nature Immunology.

[64]  A. Rudensky,et al.  Foxp3 programs the development and function of CD4+CD25+ regulatory T cells , 2003, Nature Immunology.

[65]  Edward Y. Kim,et al.  TNF Type 2 Receptor (p75) Lowers the Threshold of T Cell Activation1 , 2001, The Journal of Immunology.

[66]  T. Schumacher,et al.  Synergism of Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Depletion of Cd25+ Regulatory T Cells in Antitumor Therapy Reveals Alternative Pathways for Suppression of Autoreactive Cytotoxic T Lymphocyte Responses , 2001, The Journal of experimental medicine.

[67]  M. Chang,et al.  Association of p53 and BCL‐2 expression with Epstein‐Barr virus infection in the cancers of head and neck , 2001, Head & neck.

[68]  G. Catalano,et al.  Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival , 2000, Cancer Immunology, Immunotherapy.

[69]  R. W. Armstrong,et al.  Nasopharyngeal carcinoma in Malaysian Chinese: Salted fish and other dietary exposures , 1998, International journal of cancer.

[70]  Y. L. Chang,et al.  Elevated levels of soluble interleukin 2 receptor and tumor necrosis factor in nasopharyngeal carcinoma. , 1991, Archives of otolaryngology--head & neck surgery.

[71]  T. Zhao,et al.  Tumor necrosis factor receptor 2 promotes growth of colorectal cancer via the PI3K/AKT signaling pathway. , 2017, Oncology letters.

[72]  P. Brodt,et al.  The diverse roles of the TNF axis in cancer progression and metastasis. , 2016, Trends in cancer research.

[73]  S. Cai,et al.  Expression of CD4+CD25+ regulatory T cells and Foxp3 in peripheral blood of patients with gastric carcinoma. , 2016, Journal of Biological Regulators and Homeostatic Agents.

[74]  J. Krejsek,et al.  Regulatory T cells (TREG) and their roles in immune system with respect to immunopathological disorders. , 2010, Acta medica.

[75]  Xin Chen,et al.  TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. , 2010, Current directions in autoimmunity.

[76]  Ray H. Baughman,et al.  Supporting Online Material , 2003 .